{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:25:18Z","timestamp":1793305518675,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Research Project of Jiangsu Commission of Health","award":["Z2022019"],"award-info":[{"award-number":["Z2022019"]}]},{"name":"General program of National Natural Science Foundation of China","award":["82272671"],"award-info":[{"award-number":["82272671"]}]},{"name":"Cadre Health Research Project of Jiangsu Province","award":["BJ21030"],"award-info":[{"award-number":["BJ21030"]}]},{"name":"Wu Jieping Fund","award":["320.6750.2021-2-73"],"award-info":[{"award-number":["320.6750.2021-2-73"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Nanoparticle polymeric micellar paclitaxel (NPMP) is a novel Cremophor EL (CrEL)-free nanoparticle micellar formulation of paclitaxel. This study evaluated the efficacy and toxicity of NPMP in the treatment of patients with advanced gastric cancer (AGC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with histologically confirmed AGC in Jiangsu Cancer Hospital were retrospectively collected and divided into two groups. Patients in group A received NPMP at a total dose of 360\u00a0mg\/m<jats:sup>2<\/jats:sup> each cycle, and patients in group B were given paclitaxel at a dose of 210\u00a0mg\/m<jats:sup>2<\/jats:sup> each cycle. In addition, all patients received 5-fluorouracil at a dose of 0.75\u00a0g\/m<jats:sup>2<\/jats:sup> on days 1\u20134 and leucovorin at a dose of 200\u00a0mg\/m<jats:sup>2<\/jats:sup> on days 1\u20134 for at least 2 cycles.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From January 2021 to May 2023, 63 patients (32 in group A and 31 in group B) could be evaluated for treatment response. A marked disparity in the overall response was observed between groups A and B, indicating statistical significance<jats:italic>.<\/jats:italic> The overall response rate was 31% in group A (10\/32) and 10% in group B (3\/31) (<jats:italic>P<\/jats:italic>\u2009=\u20090.034). Disease control rate was 91% in group A (29\/32) and 81% in group B (25\/31) (<jats:italic>P<\/jats:italic>\u2009=\u20090.440). No statistically significant difference in adverse reactions was observed between the two groups. However, the incidence of anemia, leucopenia, nausea, vomiting, diarrhea, liver dysfunction, and allergy in group A was notably lower than that in group B.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>NPMP combined chemotherapy offers a new, active, and safe treatment for patients with AGC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12029-024-01058-y","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T07:02:22Z","timestamp":1714114942000},"page":"1105-1110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Nanoparticle Polymeric Micellar Paclitaxel Versus Paclitaxel for Patients with Advanced Gastric Cancer"],"prefix":"10.1007","volume":"55","author":[{"given":"Fei-Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-En","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"issue":"3","key":"1058_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"1058_CR2","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.3390\/ijms21114012","volume":"21","author":"J Machlowska","year":"2020","unstructured":"Machlowska J, Baj J, Sitarz M, et al. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21(11):4012.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1058_CR3","first-page":"635","volume":"30","author":"BA Chan","year":"2016","unstructured":"Chan BA, Jang RW, Wong RKS, et al. Improving outcomes in resectable gastric cancer: a review of current and future strategies. Oncology (Williston Park, NY). 2016;30(7):635\u201345.","journal-title":"Oncology (Williston Park, N.Y.)"},{"issue":"10","key":"1058_CR4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320.","journal-title":"Ann Oncol"},{"issue":"8","key":"1058_CR5","first-page":"CD004064","volume":"8","author":"AD Wagner","year":"2017","unstructured":"Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):CD004064.","journal-title":"Cochrane Database Syst Rev"},{"key":"1058_CR6","unstructured":"NCCN clinical practice guidelines in oncology: gastric cancer. Version 2. 2023.\u00a0https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf."},{"issue":"1","key":"1058_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5301\/tj.5000665","volume":"104","author":"YQ Lan","year":"2018","unstructured":"Lan YQ, Wu RP, Huang XB, et al. Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer. Tumori. 2018;104(1):22\u20139.","journal-title":"Tumori"},{"issue":"4","key":"1058_CR8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00280-019-03887-2","volume":"84","author":"G Roviello","year":"2019","unstructured":"Roviello G, Conter FU, Mini E, et al. Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer. Cancer Chemother Pharmacol. 2019;84(4):669\u201377.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"1058_CR9","first-page":"1454","volume":"59","author":"A Sparreboom","year":"1999","unstructured":"Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999;59(7):1454\u20137.","journal-title":"Cancer Res"},{"issue":"13","key":"1058_CR10","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","volume":"37","author":"H Gelderblom","year":"2001","unstructured":"Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590\u20138.","journal-title":"Eur J Cancer"},{"issue":"5 Suppl","key":"1058_CR11","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1177\/10600280940280S503","volume":"28","author":"RT Dorr","year":"1994","unstructured":"Dorr RT. Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother. 1994;28(5 Suppl):S11-14.","journal-title":"Ann Pharmacother"},{"issue":"12","key":"1058_CR12","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1093\/annonc\/mdm374","volume":"18","author":"DW Kim","year":"2007","unstructured":"Kim DW, Kim SY, Kim HK, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007;18(12):2009\u201314.","journal-title":"Ann Oncol"},{"issue":"2","key":"1058_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10549-007-9591-y","volume":"108","author":"KS Lee","year":"2008","unstructured":"Lee KS, Chung HC, Im SA, et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008;108(2):241\u201350.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1058_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10637-017-0506-4","volume":"36","author":"M Shi","year":"2018","unstructured":"Shi M, Sun J, Zhou J, et al. Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies. Invest New Drugs. 2018;36(2):269\u201377.","journal-title":"Invest New Drugs"},{"issue":"1","key":"1058_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.annonc.2020.10.479","volume":"32","author":"M Shi","year":"2021","unstructured":"Shi M, Gu A, Tu H, et al. Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial. Ann Oncol. 2021;32(1):85\u201396.","journal-title":"Ann Oncol"},{"issue":"11","key":"1058_CR16","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00259-016-3420-7","volume":"43","author":"J Shang","year":"2016","unstructured":"Shang J, Ling X, Zhang L, et al. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2016;43(11):1945\u201353.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"18","key":"1058_CR17","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","volume":"24","author":"AD Wagner","year":"2006","unstructured":"Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1058_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1023\/A:1008243606668","volume":"8","author":"B Glimelius","year":"1997","unstructured":"Glimelius B, Ekstr\u00f6m K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8(2):163\u20138.","journal-title":"Ann Oncol"},{"issue":"4","key":"1058_CR19","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1007\/s12029-018-0145-9","volume":"50","author":"FM de Alencar Camara Vieira","year":"2019","unstructured":"de Alencar Camara Vieira FM, de Souza Victorino APO, de Iracema Gomes Cubero D, et al. Treatment patterns among patients with metastatic and\/or unresectable gastric cancer in Brazil. J Gastrointest Cancer. 2019;50(4):780\u201393.","journal-title":"J Gastrointest Cancer"},{"issue":"9","key":"1058_CR20","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","volume":"26","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435\u201342.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1058_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4143\/crt.2010.42.1.18","volume":"42","author":"HH Lee","year":"2010","unstructured":"Lee HH, Hur H, Kim SH, et al. Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis. Cancer Res Treat. 2010;42(1):18\u201323.","journal-title":"Cancer Res Treat"},{"issue":"2","key":"1058_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3892\/ol.2011.496","volume":"3","author":"HS Kim","year":"2012","unstructured":"Kim HS, Kim JH, Kim HJ, et al. Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status. Oncol Lett. 2012;3(2):425\u20138.","journal-title":"Oncol Lett"},{"key":"1058_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12029-016-9806-8","volume":"47","author":"B Cetin","year":"2016","unstructured":"Cetin B, Gumusay O, Cengiz M, et al. Advances of molecular targeted therapy in gastric Cancer. J Gastrointest Cancer. 2016;47:125\u201334.","journal-title":"J Gastrointest Cancer"},{"key":"1058_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"1058_CR25","doi-asserted-by":"crossref","unstructured":"Tsuji K, Miyajima S, Kito Y. Nivolumab rechallenge after prior nivolumab therapy in advanced gastric cancer: a single-center case series and literature review. J Gastrointest Cancer. 2024.","DOI":"10.1007\/s12029-023-01011-5"},{"issue":"4","key":"1058_CR26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/00000421-199808000-00021","volume":"21","author":"A Ohtsu","year":"1998","unstructured":"Ohtsu A, Boku N, Tamura F, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol. 1998;21(4):416\u20139.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"1058_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s101200200015","volume":"5","author":"K Yamaguchi","year":"2002","unstructured":"Yamaguchi K, Tada M, Horikoshi N, et al. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer. 2002;5(2):90\u20135.","journal-title":"Gastric Cancer"},{"key":"1058_CR28","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224\u201335.","journal-title":"Lancet Oncol"},{"key":"1058_CR29","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1007\/s12029-022-00865-5","volume":"54","author":"G Roviello","year":"2023","unstructured":"Roviello G, Martina C, Winchler C, et al. Correlation between tumor response and survival outcomes in patients with advanced gastric cancer receiving ramucirumab and paclitaxel as second-line therapy. J Gastrointest Cancer. 2023;54:802\u20138.","journal-title":"J Gastrointest Cancer"},{"issue":"6","key":"1058_CR30","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00280-018-3576-x","volume":"81","author":"YQ Lan","year":"2018","unstructured":"Lan YQ, Kong LJ, Lin XY, et al. Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. Cancer Chemother Pharmacol. 2018;81(6):1007\u201315.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"1058_CR31","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2347::AID-CNCR8>3.0.CO;2-8","volume":"85","author":"JJ Lokich","year":"1999","unstructured":"Lokich JJ, Sonneborn H, Anderson NR, et al. Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas. Cancer. 1999;85(11):2347\u201351.","journal-title":"Cancer"},{"issue":"6","key":"1058_CR32","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00280-007-0433-8","volume":"60","author":"JG Kim","year":"2007","unstructured":"Kim JG, Sohn SK, Song HS, et al. Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol. 2007;60(6):863\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"1058_CR33","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/00001813-200206000-00008","volume":"13","author":"F Honecker","year":"2002","unstructured":"Honecker F, Kollmannsberger C, Quietzsch D, et al. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs. 2002;13(5):497\u2013503.","journal-title":"Anticancer Drugs"},{"issue":"4","key":"1058_CR34","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1159\/000227702","volume":"54","author":"CH Hsu","year":"1997","unstructured":"Hsu CH, Yeh KH, Chen LT, et al. Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers.\u00a0An effective and low-toxic regimen for patients with poor general condition. Oncology. 1997;54(4):275\u201380.","journal-title":"Oncology"},{"issue":"5","key":"1058_CR35","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/bjc.1996.425","volume":"74","author":"Y Kano","year":"1996","unstructured":"Kano Y, Akutsu M, Tsunoda S, et al. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer. 1996;74(5):704\u201310.","journal-title":"Br J Cancer"},{"issue":"4","key":"1058_CR36","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1179\/joc.2007.19.4.444","volume":"19","author":"M Ninomiya","year":"2007","unstructured":"Ninomiya M, Kondo K, Matsuo K, et al. Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma. J Chemother. 2007;19(4):444\u201350.","journal-title":"J Chemother"},{"issue":"2","key":"1058_CR37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00280-007-0508-6","volume":"61","author":"CK Im","year":"2008","unstructured":"Im CK, Jeung HC, Rha SY, et al. A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. Cancer Chemother Pharmacol. 2008;61(2):315\u201321.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1058_CR38","first-page":"621","volume":"15","author":"BC Cho","year":"2006","unstructured":"Cho BC, Kim JH, Kim CB, et al. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer. Oncol Rep. 2006;15(3):621\u20137.","journal-title":"Oncol Rep"},{"issue":"4","key":"1058_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/COC.0b013e3181e84b63","volume":"34","author":"F Wang","year":"2011","unstructured":"Wang F, Wang Z, Zhou N, et al. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Am J Clin Oncol. 2011;34(4):401\u20135.","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"1058_CR40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00280-008-0752-4","volume":"63","author":"HJ Lee","year":"2009","unstructured":"Lee HJ, Cho DY, Park JC, et al. Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer. Cancer Chemother Pharmacol. 2009;63(3):427\u201332.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"1058_CR41","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/00000421-199912000-00008","volume":"22","author":"AM Murad","year":"1999","unstructured":"Murad AM, Petroianu A, Guimaraes RC, et al. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol. 1999;22(6):580\u20136.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"1058_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10120-009-0505-z","volume":"12","author":"J Sakamoto","year":"2009","unstructured":"Sakamoto J, Matsui T, Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2009;12(2):69\u201378.","journal-title":"Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association"},{"issue":"13","key":"1058_CR43","doi-asserted-by":"publisher","first-page":"6370","DOI":"10.7150\/thno.57828","volume":"11","author":"G Wei","year":"2021","unstructured":"Wei G, Wang Y, Yang G, et al. Recent progress in nanomedicine for enhanced cancer chemotherapy. Theranostics. 2021;11(13):6370\u201392.","journal-title":"Theranostics"},{"key":"1058_CR44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.actbio.2020.12.009","volume":"121","author":"M Norouzi","year":"2021","unstructured":"Norouzi M, Hardy P. Clinical applications of nanomedicines in lung cancer treatment. Acta Biomater. 2021;121:134\u201342.","journal-title":"Acta Biomater"},{"key":"1058_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121961","volume":"623","author":"J Lu","year":"2022","unstructured":"Lu J, Gu A, Wang W, et al. Polymeric micellar paclitaxel (Pm-Pac) prolonged overall survival for NSCLC patients without pleural metastasis. Int J Pharm. 2022;623: 121961.","journal-title":"Int J Pharm"},{"issue":"17","key":"1058_CR46","first-page":"3752","volume":"55","author":"F Yuan","year":"1995","unstructured":"Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55(17):3752\u20136.","journal-title":"Cancer Res"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01058-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-024-01058-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01058-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T03:33:57Z","timestamp":1724729637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-024-01058-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1058"],"URL":"https:\/\/doi.org\/10.1007\/s12029-024-01058-y","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]},"assertion":[{"value":"20 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}]}}